TY  - JOUR
AU  - Solomun, Ljiljana
AU  - Ibrić, Svetlana
AU  - Boltić, Zorana
AU  - Đurić, Zorica
AU  - Stupar, Biljana
PY  - 2008
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1024
AB  - The unique approach in manufacturing of pharmaceutical dosage forms of active substances known to be unstable in aqueous solution is the introduction of lyophilization process. Nevertheless, these products must be reconstituted using the diluent from a separate container before application. The possible solution for this problem is the application of dual chamber vials comprising the freeze-dried product in a lower compartment of the vial and the solution for reconstitution in the upper chamber. The main issue in development of such product is the choice of contact packaging (rubber closures, glass vials and the container closure system as a whole). The most important parameter used for evaluation of the influence of contact material on product quality was the pH value. The results have shown that the type of vials (moulded or tubular glass) has no impact on pH shift of the solution for reconstitution (tested solution-TS), while significant differences in pH value of the TS were observed depending on the rubber closures formulation used (with some formulations, the pH shift during the test was 6.5-9.14). Benzyl alcohol assay during the tests remained unchanged. Integrity tests of the container closure system (CCS) have demonstrated the adequacy of the selected packaging system. The quality of the CCS of choice was confirmed in the course of stability studies, only parameters directly influenced by CCS being presented in this work: loss on drying and pH value. On the basis of these results, no changes in loss on drying were connected to CCS, and the pH value of the reconstituted solution remains unchanged in samples tested both ex-tempore and after in-use period of 48 h.
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Journal of Pharmaceutical and Biomedical Analysis
T1  - The impact of primary packaging on the quality of parenteral products
VL  - 48
IS  - 3
SP  - 744
EP  - 748
DO  - 10.1016/j.jpba.2008.07.025
ER  - 

@article{
author = "Solomun, Ljiljana and Ibrić, Svetlana and Boltić, Zorana and Đurić, Zorica and Stupar, Biljana",
year = "2008",
abstract = "The unique approach in manufacturing of pharmaceutical dosage forms of active substances known to be unstable in aqueous solution is the introduction of lyophilization process. Nevertheless, these products must be reconstituted using the diluent from a separate container before application. The possible solution for this problem is the application of dual chamber vials comprising the freeze-dried product in a lower compartment of the vial and the solution for reconstitution in the upper chamber. The main issue in development of such product is the choice of contact packaging (rubber closures, glass vials and the container closure system as a whole). The most important parameter used for evaluation of the influence of contact material on product quality was the pH value. The results have shown that the type of vials (moulded or tubular glass) has no impact on pH shift of the solution for reconstitution (tested solution-TS), while significant differences in pH value of the TS were observed depending on the rubber closures formulation used (with some formulations, the pH shift during the test was 6.5-9.14). Benzyl alcohol assay during the tests remained unchanged. Integrity tests of the container closure system (CCS) have demonstrated the adequacy of the selected packaging system. The quality of the CCS of choice was confirmed in the course of stability studies, only parameters directly influenced by CCS being presented in this work: loss on drying and pH value. On the basis of these results, no changes in loss on drying were connected to CCS, and the pH value of the reconstituted solution remains unchanged in samples tested both ex-tempore and after in-use period of 48 h.",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Journal of Pharmaceutical and Biomedical Analysis",
title = "The impact of primary packaging on the quality of parenteral products",
volume = "48",
number = "3",
pages = "744-748",
doi = "10.1016/j.jpba.2008.07.025"
}

Solomun, L., Ibrić, S., Boltić, Z., Đurić, Z.,& Stupar, B.. (2008). The impact of primary packaging on the quality of parenteral products. in Journal of Pharmaceutical and Biomedical Analysis
Pergamon-Elsevier Science Ltd, Oxford., 48(3), 744-748.
https://doi.org/10.1016/j.jpba.2008.07.025

Solomun L, Ibrić S, Boltić Z, Đurić Z, Stupar B. The impact of primary packaging on the quality of parenteral products. in Journal of Pharmaceutical and Biomedical Analysis. 2008;48(3):744-748.
doi:10.1016/j.jpba.2008.07.025 .

Solomun, Ljiljana, Ibrić, Svetlana, Boltić, Zorana, Đurić, Zorica, Stupar, Biljana, "The impact of primary packaging on the quality of parenteral products" in Journal of Pharmaceutical and Biomedical Analysis, 48, no. 3 (2008):744-748,
https://doi.org/10.1016/j.jpba.2008.07.025 . .

TY  - JOUR
AU  - Ibrić, Svetlana
AU  - Jovanović, M
AU  - Đurić, Zorica
AU  - Parojčić, Jelena
AU  - Petrović, Slobodan D.
AU  - Solomun, Ljiljana
AU  - Stupar, Biljana
PY  - 2003
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/469
AB  - The purpose of the present study was to model the effects of the concentration of Eudragit L 100 and compression pressure as the most important process and formulation variables on the in vitro release profile of aspirin from matrix tablets formulated with Eudragit L 100 as matrix substance and to optimize the formulation by artificial neural network. As model formulations, 10 kinds of aspirin matrix tablets were prepared. The amount of Eudragit L 100 and the compression pressure were selected as causal factors. In vitro dissolution time profiles at 4 different sampling times were chosen as responses. A set of release parameters and causal factors were used as tutorial data for the generalized regression neural network (GRNN) and analyzed using a computer. Observed results of drug release studies indicate that drug release rates vary widely between investigated formulations, with a range of 5 hours to more than 10 hours to complete dissolution. The GRNN model was optimized. The root mean square value for the trained network was 1.12%, which indicated that the optimal GRNN model was reached. Applying the generalized distance function method, the optimal tablet formulation predicted by GRNN was with 5% of Eudragit L 100 and tablet hardness 60N. Calculated difference (f1 2.465) and similarity (f2 85.61) factors indicate that there is no difference between predicted and experimentally observed drug release profiles for the optimal formulation. This work illustrates the potential for an artificial neural network, GRNN, to assist in development of extended release dosage forms.
PB  - AAPS PharmSci Editorial Office
T2  - AAPS PharmSciTech
T1  - Artificial neural networks in the modeling and optimization of aspirin extended release tablets with Eudragit L 100 as matrix substance
VL  - 4
IS  - 1
DO  - 10.1208/pt040109
ER  - 

@article{
author = "Ibrić, Svetlana and Jovanović, M and Đurić, Zorica and Parojčić, Jelena and Petrović, Slobodan D. and Solomun, Ljiljana and Stupar, Biljana",
year = "2003",
abstract = "The purpose of the present study was to model the effects of the concentration of Eudragit L 100 and compression pressure as the most important process and formulation variables on the in vitro release profile of aspirin from matrix tablets formulated with Eudragit L 100 as matrix substance and to optimize the formulation by artificial neural network. As model formulations, 10 kinds of aspirin matrix tablets were prepared. The amount of Eudragit L 100 and the compression pressure were selected as causal factors. In vitro dissolution time profiles at 4 different sampling times were chosen as responses. A set of release parameters and causal factors were used as tutorial data for the generalized regression neural network (GRNN) and analyzed using a computer. Observed results of drug release studies indicate that drug release rates vary widely between investigated formulations, with a range of 5 hours to more than 10 hours to complete dissolution. The GRNN model was optimized. The root mean square value for the trained network was 1.12%, which indicated that the optimal GRNN model was reached. Applying the generalized distance function method, the optimal tablet formulation predicted by GRNN was with 5% of Eudragit L 100 and tablet hardness 60N. Calculated difference (f1 2.465) and similarity (f2 85.61) factors indicate that there is no difference between predicted and experimentally observed drug release profiles for the optimal formulation. This work illustrates the potential for an artificial neural network, GRNN, to assist in development of extended release dosage forms.",
publisher = "AAPS PharmSci Editorial Office",
journal = "AAPS PharmSciTech",
title = "Artificial neural networks in the modeling and optimization of aspirin extended release tablets with Eudragit L 100 as matrix substance",
volume = "4",
number = "1",
doi = "10.1208/pt040109"
}

Ibrić, S., Jovanović, M., Đurić, Z., Parojčić, J., Petrović, S. D., Solomun, L.,& Stupar, B.. (2003). Artificial neural networks in the modeling and optimization of aspirin extended release tablets with Eudragit L 100 as matrix substance. in AAPS PharmSciTech
AAPS PharmSci Editorial Office., 4(1).
https://doi.org/10.1208/pt040109

Ibrić S, Jovanović M, Đurić Z, Parojčić J, Petrović SD, Solomun L, Stupar B. Artificial neural networks in the modeling and optimization of aspirin extended release tablets with Eudragit L 100 as matrix substance. in AAPS PharmSciTech. 2003;4(1).
doi:10.1208/pt040109 .

Ibrić, Svetlana, Jovanović, M, Đurić, Zorica, Parojčić, Jelena, Petrović, Slobodan D., Solomun, Ljiljana, Stupar, Biljana, "Artificial neural networks in the modeling and optimization of aspirin extended release tablets with Eudragit L 100 as matrix substance" in AAPS PharmSciTech, 4, no. 1 (2003),
https://doi.org/10.1208/pt040109 . .

TY  - CONF
AU  - Solomun, Ljiljana
AU  - Cvetićanin-Ilić, S.
AU  - Stupar, Biljana
AU  - Aćimović, D.
AU  - Jovanović, M.
PY  - 2002
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/409
PB  - Savez farmaceutskih udruženja Srbije, Beograd
C3  - Arhiv za farmaciju
T1  - Photostability of drugs - nifedipine
T1  - Fotostabilnost lekova - nifedipin
VL  - 52
IS  - 4
SP  - 538
EP  - 539
UR  - https://hdl.handle.net/21.15107/rcub_farfar_409
ER  - 

@conference{
author = "Solomun, Ljiljana and Cvetićanin-Ilić, S. and Stupar, Biljana and Aćimović, D. and Jovanović, M.",
year = "2002",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Photostability of drugs - nifedipine, Fotostabilnost lekova - nifedipin",
volume = "52",
number = "4",
pages = "538-539",
url = "https://hdl.handle.net/21.15107/rcub_farfar_409"
}

Solomun, L., Cvetićanin-Ilić, S., Stupar, B., Aćimović, D.,& Jovanović, M.. (2002). Photostability of drugs - nifedipine. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 52(4), 538-539.
https://hdl.handle.net/21.15107/rcub_farfar_409

Solomun L, Cvetićanin-Ilić S, Stupar B, Aćimović D, Jovanović M. Photostability of drugs - nifedipine. in Arhiv za farmaciju. 2002;52(4):538-539.
https://hdl.handle.net/21.15107/rcub_farfar_409 .

Solomun, Ljiljana, Cvetićanin-Ilić, S., Stupar, Biljana, Aćimović, D., Jovanović, M., "Photostability of drugs - nifedipine" in Arhiv za farmaciju, 52, no. 4 (2002):538-539,
https://hdl.handle.net/21.15107/rcub_farfar_409 .

TY  - CONF
AU  - Palurović, Branka
AU  - Stupar, Biljana
AU  - Knežević, Tanja
AU  - Vuković, S.
AU  - Ibrić, Svetlana
PY  - 2002
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/412
PB  - Savez farmaceutskih udruženja Srbije, Beograd
C3  - Arhiv za farmaciju
T1  - Critical factors for formulation and preparation process of the product Nifedipin pellets
T1  - Kritični faktori za formulaciju i proces izrade proizvoda Nifedipin peleta
VL  - 52
IS  - 4
SP  - 540
EP  - 541
UR  - https://hdl.handle.net/21.15107/rcub_farfar_412
ER  - 

@conference{
author = "Palurović, Branka and Stupar, Biljana and Knežević, Tanja and Vuković, S. and Ibrić, Svetlana",
year = "2002",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Critical factors for formulation and preparation process of the product Nifedipin pellets, Kritični faktori za formulaciju i proces izrade proizvoda Nifedipin peleta",
volume = "52",
number = "4",
pages = "540-541",
url = "https://hdl.handle.net/21.15107/rcub_farfar_412"
}

Palurović, B., Stupar, B., Knežević, T., Vuković, S.,& Ibrić, S.. (2002). Critical factors for formulation and preparation process of the product Nifedipin pellets. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 52(4), 540-541.
https://hdl.handle.net/21.15107/rcub_farfar_412

Palurović B, Stupar B, Knežević T, Vuković S, Ibrić S. Critical factors for formulation and preparation process of the product Nifedipin pellets. in Arhiv za farmaciju. 2002;52(4):540-541.
https://hdl.handle.net/21.15107/rcub_farfar_412 .

Palurović, Branka, Stupar, Biljana, Knežević, Tanja, Vuković, S., Ibrić, Svetlana, "Critical factors for formulation and preparation process of the product Nifedipin pellets" in Arhiv za farmaciju, 52, no. 4 (2002):540-541,
https://hdl.handle.net/21.15107/rcub_farfar_412 .